Publisher: Blackwell Publishing
E-ISSN: 1097-0142|121|23|4165-4172
ISSN: 0008-543X
Source: Cancer, Vol.121, Iss.23, 2015-12, pp. : 4165-4172
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Treatment options for patients with non–small cell lung cancer (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood-brain barrier–penetrating, microtubule-targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies in patients with NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases. This is the first prospective study of chemotherapy for recurrent brain metastases from non–small cell lung cancer. In this population, patupilone demonstrates activity in heavily treated patients.
Related content
By Tran Hai Zinner Ralph Blumenschein George Oh Yun Papadimitrakopoulou Vassiliki Kim Edward Lu Charles Malik Mubashira Lum Bert Herbst Roy
Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. :